Company’s 36-month beta value is 1.30.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for PROK is 76.66M, and currently, short sellers hold a 13.17% ratio of that floaft. The average trading volume of PROK on September 19, 2024 was 514.10K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PROK) stock’s latest price update
ProKidney Corp (NASDAQ: PROK)’s stock price has decreased by 0.00 compared to its previous closing price of 2.39. However, the company has seen a -0.42% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-03 that WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentially preserve kidney function in patients with type 2 diabetes and advanced CKD.
PROK’s Market Performance
ProKidney Corp (PROK) has seen a -0.42% fall in stock performance for the week, with a -0.42% decline in the past month and a -10.82% plunge in the past quarter. The volatility ratio for the week is 4.20%, and the volatility levels for the past 30 days are at 6.49% for PROK. The simple moving average for the last 20 days is 1.98% for PROK stock, with a simple moving average of 13.21% for the last 200 days.
Analysts’ Opinion of PROK
Many brokerage firms have already submitted their reports for PROK stocks, with Guggenheim repeating the rating for PROK by listing it as a “Buy.” The predicted price for PROK in the upcoming period, according to Guggenheim is $6 based on the research report published on September 10, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see PROK reach a price target of $3. The rating they have provided for PROK stocks is “Equal-Weight” according to the report published on March 07th, 2024.
PROK Trading at 4.69% from the 50-Day Moving Average
After a stumble in the market that brought PROK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.95% of loss for the given period.
Volatility was left at 6.49%, however, over the last 30 days, the volatility rate increased by 4.20%, as shares surge +2.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.40% lower at present.
During the last 5 trading sessions, PROK fell by -0.42%, which changed the moving average for the period of 200-days by +42.26% in comparison to the 20-day moving average, which settled at $2.35. In addition, ProKidney Corp saw 34.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PROK starting from Weber Darin J., who sale 826 shares at the price of $2.50 back on Jul 26 ’24. After this action, Weber Darin J. now owns 119,892 shares of ProKidney Corp, valued at $2,065 using the latest closing price.
Control Empresarial de Capital, the Add’l Rep. Persons-see Ex.99-1 of ProKidney Corp, purchase 8,264,462 shares at $2.42 during a trade that took place back on Jun 11 ’24, which means that Control Empresarial de Capital is holding 71,560,107 shares at $19,999,998 based on the most recent closing price.
Stock Fundamentals for PROK
Current profitability levels for the company are sitting at:
- -30.58 for the present operating margin
- 0.18 for the gross margin
The net margin for ProKidney Corp stands at -13.06. The total capital return value is set at -0.29.
Based on ProKidney Corp (PROK), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -18.3. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -22906.0.
Currently, EBITDA for the company is -148.35 million with net debt to EBITDA at 1.54. When we switch over and look at the enterprise to sales, we see a ratio of 107.81. The receivables turnover for the company is 1.64for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.87.
Conclusion
In a nutshell, ProKidney Corp (PROK) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
